

Aarhus 2024 05 29

Brief report from The Nordic Pancreas and Islet Transplant Group (NπTG) We've had two meetings with our group the last year. One face to face at Arlanda Airport in Stockholm in October and one over Zoom in April

#### Main subjects discussed

- Fewer pancreas offers to the islet labs. Compared to pre-covid there has been a substantial reduction, not explained by figures for whole pancreas transplantations. Coordinators etc have been informed and figures analyzed, but registrations regarding why pancreases have been discarded are a bit blunt and a full explanation of the situation hasn't emerged yet
- Registries. There are now possibilities to enter data for pancreas as well as islet transplantation in YASWA. There are variations between centers regarding how diligent reporting is. The common waiting list for islet transplantation is being moved to YASWA. The registry is also prepared to receive data regarding auto-islet transplantation and contacts are taken with gastro-surgeons regarding this.
- Two clinical trials have been in focus. Oslo is taking active part and representing the PI group in the **VX-880** study. This is an investigational allogenic stem cell-derived, fully differentiated, insulin producing islet cell therapy. No patients have been transplanted in the Nordics yet, but in the study 14 patients have now received the product. All patients have demonstrated islet cell engraftment and production of endogenous insulin. All patients in part A and B (except one that withdrew consent) demonstrate glycemic control (HbA1c < 7% (53 mmol/mol)) and no longer require exogenous insulin. There have been two deaths. The causes of death are stated not to be related to VX-880, but the study is temporarily paused for safety evaluation. Most Nordic islet transplanting centers have participated in **NNCIT-02**. A higher dose of low molecular weight dextran sulphate compared to previous trials was given to the patient at transplantation to facilitate engraftment. Following a SAE with a post transplantation bleeding in the fall there was a major bleeding in a new patient in February where the right branch of the liver artery had to be coiled to get control of the situation. The trial has due to this been closed on recommendation from the safety committee and all clinical islet transplantation was temporarily stopped by the PI of the trial/co-chair of this group until the situation could be assessed. This was a main topic at the April meeting and centers are starting to transplant again after discussions with local angio-departments.
- 

Minutes from the meetings are published on Scandiatransplant web page

Next meeting is planned for Oct 15 at Arlanda

On behalf of NπTG

Torbjörn Lundgren

Co Chairman (together w Hanne Scholtz, Oslo)

Karolinska Stockholm